NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $143,697 | -55.6% | 204,434 | +42.9% | 0.00% | -100.0% |
| Q4 2022 | $323,322 | -64.5% | 143,063 | +113.3% | 0.00% | 0.0% |
| Q4 2021 | $910,000 | +145.3% | 67,060 | +224.4% | 0.00% | – |
| Q3 2021 | $371,000 | -15.9% | 20,670 | -19.5% | 0.00% | – |
| Q2 2021 | $441,000 | -14.0% | 25,670 | 0.0% | 0.00% | – |
| Q1 2021 | $513,000 | +18.5% | 25,670 | -1.7% | 0.00% | -100.0% |
| Q3 2020 | $433,000 | -41.2% | 26,115 | -18.0% | 0.00% | 0.0% |
| Q2 2020 | $737,000 | +10.2% | 31,832 | -15.0% | 0.00% | 0.0% |
| Q1 2020 | $669,000 | -45.9% | 37,458 | -34.6% | 0.00% | 0.0% |
| Q4 2019 | $1,236,000 | +485.8% | 57,237 | +393.3% | 0.00% | – |
| Q3 2019 | $211,000 | -84.5% | 11,603 | -69.7% | 0.00% | -100.0% |
| Q2 2019 | $1,361,000 | +1.6% | 38,250 | -4.0% | 0.00% | 0.0% |
| Q1 2019 | $1,339,000 | +13.3% | 39,840 | +11.3% | 0.00% | 0.0% |
| Q4 2018 | $1,182,000 | -39.2% | 35,790 | -10.1% | 0.00% | -50.0% |
| Q2 2018 | $1,944,000 | -82.4% | 39,798 | -61.6% | 0.00% | -81.8% |
| Q1 2018 | $11,018,000 | +99.5% | 103,684 | +12.1% | 0.01% | +175.0% |
| Q4 2017 | $5,523,000 | +112.3% | 92,471 | -14.7% | 0.00% | +100.0% |
| Q3 2017 | $2,602,000 | +33.0% | 108,409 | +7.4% | 0.00% | 0.0% |
| Q2 2017 | $1,956,000 | -29.7% | 100,902 | -15.4% | 0.00% | -33.3% |
| Q1 2017 | $2,784,000 | +104.0% | 119,200 | +7.2% | 0.00% | +200.0% |
| Q4 2016 | $1,365,000 | -59.3% | 111,217 | -43.7% | 0.00% | -66.7% |
| Q3 2016 | $3,351,000 | +12.8% | 197,702 | -5.4% | 0.00% | 0.0% |
| Q2 2016 | $2,972,000 | +3.5% | 208,902 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $2,872,000 | -18.5% | 208,902 | +1.2% | 0.00% | -25.0% |
| Q4 2015 | $3,522,000 | +55.8% | 206,370 | 0.0% | 0.00% | +33.3% |
| Q3 2015 | $2,261,000 | -12.4% | 206,370 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $2,582,000 | -69.6% | 206,370 | -73.3% | 0.00% | -70.0% |
| Q1 2015 | $8,495,000 | -28.0% | 772,309 | +1.5% | 0.01% | -23.1% |
| Q4 2014 | $11,794,000 | +17.2% | 760,891 | -8.7% | 0.01% | +8.3% |
| Q3 2014 | $10,062,000 | +1.4% | 833,660 | +7.7% | 0.01% | 0.0% |
| Q2 2014 | $9,920,000 | -3.4% | 773,833 | -8.6% | 0.01% | 0.0% |
| Q1 2014 | $10,266,000 | +23.4% | 846,986 | +15.5% | 0.01% | +9.1% |
| Q4 2013 | $8,322,000 | -25.7% | 733,196 | -31.6% | 0.01% | -26.7% |
| Q3 2013 | $11,201,000 | +77.3% | 1,071,950 | +96.0% | 0.02% | +66.7% |
| Q2 2013 | $6,317,000 | – | 546,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |